denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Karyopharm Therapeutics
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Plasma Cell Disorders, Education, Diseases
Hematology Disease Topics & Pathways:
Plasma Cell Disorders, Education, Diseases
Friday, December 6, 2024: 3:00 PM-6:00 PM
Seaport Ballroom EFGH
(Manchester Grand Hyatt San Diego)
Chair:
Sagar Lonial, MD, Winship Cancer Institute, Emory University
Disclosures:
Lonial: TG Therapeutics Inc (no cancer agents currently): Membership on an entity's Board of Directors or advisory committees; AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda: Research Funding.
Speakers:
Philippe Moreau, MD, PhD, University Hospital Hôtel-Dieu
,
Paul G. Richardson, Dana-Farber Cancer Institute
,
Noopur Raje, Massachusetts General Hospital
and
Robert Z. Orlowski, MD, PhD, The University of Texas MD Anderson Cancer Center
Disclosures:
Moreau: AbbVie, Amgen, Celgene, Janssen, Oncopeptides, Roche, Sanofi: Consultancy, Honoraria. Richardson: Oncopeptides: Research Funding; Celgene/Bristol Myers Squibb, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron, Sanofi: Consultancy. Raje: Onyx Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Amgen Inc: Other: Steering Committee; Takeda Pharmaceuticals USA Inc: Membership on an entity's Board of Directors or advisory committees; Roche Laboratories Inc: Other: Steering Committee; Novartis: Membership on an entity's Board of Directors or advisory committees; Merck: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees; Caribou Biosciences Inc: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Immuneel Therapeutics: Membership on an entity's Board of Directors or advisory committees; Janssen Biotech Inc: Membership on an entity's Board of Directors or advisory committees; bluebird bio: Membership on an entity's Board of Directors or advisory committees, Research Funding. Orlowski: BioTheryX: Membership on an entity's Board of Directors or advisory committees, Research Funding; Asylia Therapeutics Inc.: Current equity holder in private company, Patents & Royalties; Bristol Myers Squibb, CARsgen Therapeutics, Exelixis Inc, Heidelberg Pharma, Janssen Biotech Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Laboratory Research Funding: Asylia Therapeutics Inc, BioTheryX Inc, Heidelberg Pharma: Research Funding; Bristol-Myers Squibb Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; DEM BioPharma, Inc., Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Myeloma 360, Nanjing IASO Biotherapeutics, Neoleukin Corporation, Oncopeptides AB, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sporos Bio: Membership on an entity's Board of Directors or advisory committees; AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, BioTheryX Inc, Bristol Myers Squibb, Karyopharm Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Nanjing IASO Biotherapeutics, Neoleukin Therapeutics, Oncopeptides, Pf: Membership on an entity's Board of Directors or advisory committees; Sanofi, Takeda Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding.
This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with multiple myeloma (MM). Five clinical investigators will serve as faculty, one of whom will moderate. Prior to the symposium. Research To Practice (RTP) recruit 4 general medical oncologists/hematologists to consult on the project. The clinicians will participate in a live working group session during which they will voice challenging questions and cases from their practices and help shape the content for the symposium. The entire session will be recorded and video segments will be adapted for presentation during the event. The agenda for the live symposium will be divided into 5 modules. To begin each module, the moderator will play select video excerpts from the working group for the audience and the faculty. Moderated panel discussion will ensue to provide expert perspectives and answers to the questions introduced. A faculty member-led review of related research findings will complete each module. To make the event even more engaging, attendees will use iPads to submit their own questions and cases, which will be introduced and addressed periodically throughout the program. Virtual attendees will have the same capability via the webcast platform.
See more of: Friday Satellite Symposia